Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, Jyssum I, Nygaard UC, Kristoffersen AB, Christensen IE, Josefsson SE, Lund KP, Chopra A, Osen JR, Chaban V, Tveter AT, Sexton J, Kvien TK, Jahnsen J, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Kared H, Lund-Johansen F et al. (2024)
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
EBioMedicine, 108, 105317 (in press)
DOI 10.1016/j.ebiom.2024.105317, PubMed 39260039

Tunheim G, Fossum E, Robertson AH, Rø GØI, Chopra A, Vaage JT, Vikse EL, Kran AB, Magnus P, Trogstad L, Mjaaland S, Hungnes O, Lund-Johansen F (2024)
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults
BMC Infect Dis, 24 (1), 841
DOI 10.1186/s12879-024-09670-w, PubMed 39164637

Wüsthoff LEC, Lund-Johansen F, Henriksen K, Wildendahl G, Jacobsen JA, Gomes L, Anjum HS, Barlinn R, Kran AB, Munthe LA, Vaage JT (2024)
Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies
Harm Reduct J, 21 (1), 120
DOI 10.1186/s12954-024-01023-9, PubMed 38890611